Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry.
I’m joined by Lisa Deschamps, CEO of AviadoBio.
After 25 years at Novartis, leading global launches in gene therapy, she’s now at the helm of AviadoBio—developing treatments for FTD and ALS.
We talk career moves, mindset, culture, and what’s ahead.
Enjoy and stay tuned.
We're honored to have Dr. Michael Kauffman, M.D., Ph.D., the Chief Executive Officer of Nereid Therapeutics, joining us.Dr. Kauffman brings over 25 years of experience in the life sciences industry, with a distinguished track record in oncology drug development. Currently, he leads Nereid Therapeutics, a company at the forefront of pioneering therapies targeting biomolecular condensates—a novel approach to treating complex diseases. Under his leadership, Nereid is advancing multiple programs in oncology and neurodegeneration toward clinical application. PR NewswirePrior to his role at Nereid, Dr. Kauffman co-founded Karyopharm Therapeutics, where he served as CEO and guided the company from discovery to the global approval of XPOVIO® for multiple myeloma and non-Hodgkin’s lymphoma. His extensive experience also includes leadership positions at Onyx Pharmaceuticals, Millennium Pharmaceuticals, and Biogen. Dr. Kauffman earned his M.D. and Ph.D. from Johns Hopkins Medical School and completed his training in Internal Medicine at Beth Israel Deaconess Medical Center and in Rheumatology at Massachusetts General Hospital. He is board-certified in Internal Medicine and licensed in Massachusetts and Florida. In this episode, we'll delve into Dr. Kauffman's journey in the biotech industry, the innovative science behind Nereid's approach, and the future of targeted therapies in treating complex diseases.
We were delighted to be joined by Julie Person on the BioHub podcast, an accomplished human resources and organizational leader with over 20 years of experience in the biopharmaceutical industry. She currently serves as Chief Administrative Officer at Third Harmonic Bio, where she leads company operations, including human resources, communications, and organizational strategy.Julie has a strong track record of helping biotech companies scale and thrive through critical growth stages. Prior to her current role, she was Chief People Officer at Neumora Therapeutics, and held senior HR leadership positions at Sangamo Therapeutics, Audentes Therapeutics, Shire, and Baxalta. Her expertise lies in building high-performing teams, shaping company culture, and aligning talent strategies with business goals.She holds a degree from Saint Mary's College of California and completed an Executive Leadership Program at the University of Michigan Ross School of Business.
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry.
I’m joined by Alexander Zehnder, CEO of CureVac — a company that’s been pioneering mRNA technology for 25 years.
Alexander stepped into the CEO role in 2023 and has been leading CureVac through a critical transformation: securing a €1.45 billion partnership with GSK, executing a strategic pivot, and driving a major cultural shift within the organization. With a background in medicine and a career spanning Roche, Genentech, and Sanofi, he brings a unique perspective on what it takes to lead at scale while staying patient-focused.
We dive into the evolution of mRNA, the story behind CureVac’s next chapter, and the mindset needed to lead through change.
Enjoy and stay tuned.
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry.
I’m joined by Dr. Claudia Zylberberg — a pioneering force in cell and gene therapy and the founder of Akron Biotech.
Claudia has spent her career shaping the future of biologics manufacturing, building Akron into a key player in the CGT ecosystem, and championing the development of global standards for advanced therapies. She’s a scientist, an entrepreneur, and an advocate for innovation, quality, and access in one of the most complex areas of biotech.
From founding startups to influencing international policy, Claudia brings a wealth of experience and insight to the table — and I can’t wait to get into it.
Enjoy and stay tuned.
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry.
On this episode of The BioHub, I’m joined by Uwe Schoenbeck, Partner at Canaan and one of the most respected names in early-stage biotech.
After more than a decade leading external science and innovation at Pfizer, Uwe made the jump to venture capital, joining Canaan in 2023. With a background spanning big pharma, startups, and science itself—he’s uniquely positioned to see what’s coming next.
In this episode, we talk about the shift from pharma to VC, what founders get wrong when pitching, and the traits that separate the good companies from the great ones.
Enjoy and stay tuned.
Our little spin off of our time at JPM!
Big announcements and exclusives! Here we have David Happel, CEO of Sagimet Biosciences
Listen to hear how they've been doing.
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry.
I’m joined by Gwen Acton, CEO of Vivo Group and an expert in leadership development for scientists, engineers, and biotech professionals.
Gwen has had a fascinating career—she earned a PhD from MIT, was a faculty member at Harvard, ran operations at the Whitehead Institute during the Human Genome Project, and has helped thousands of technical experts become stronger leaders.
Now, she’s adding “author” to her resume with a brand-new book on leadership, and today, we’re diving into why leadership is so crucial in biotech, how it’s evolved, and what inspired her to write it.
Enjoy and stay tuned
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry.Today we're joined by David De Graaf, CEO of Co-Founder of Reverb TherapeuticsDavid has an incredible background, with positions at companies such as AstraZeneca, Pfizer, Apple Tree Partners & Boehringer Ingelheim as well being at the helm of multiple successful biotechs. In this episode, we dive into his journey, building out seed stage biotech's from scratch as well as the Canadian Biotech scene
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry.
I’m joined by Judy Chou, CEO of AltruBio—one of the mostexciting biotech companies out there, especially after closing the largest Series B in biotech over the last four years.
Judy has an incredible background, having led global biotechat Bayer, held leadership roles at Pfizer, and served as research faculty at Harvard. Now, as the CEO of AltruBio, she’s driving the company’s mission to develop first-in-class immune modulators for autoimmune and inflammatorydiseases.
In this episode, we dive into her journey, how AltruBio isthriving in a tough market, and what’s ahead for the company in 2024. Let’s get into it!
Enjoy and stay Tuned.
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry.
I’m joined by Aoife Brennan, CEO of Climb Bio—a company at the cutting edge of pioneering new approaches to cell and gene therapy.
Aoife is a seasoned biotech leader with a track record of driving innovation. Before joining Climb Bio, she was the CEO of Synlogic, where she led the company through critical clinical advancements in engineered probiotic medicines.
With a background in medicine and deep experience in biotech strategy, she has a unique perspective on bridging science and business to create transformative therapies.
In this episode, we talk about her journey, what makes Climb Bio’s approach different, and how she’s navigating leadership in an ever-evolving industry.
Enjoy and stay Tuned.
Thank you for tuning into another episode of Bio Hub! Today, we have the privilege of hosting Shalabh Gupta, a seasoned leader in the biotech industry and the current Founder, Chairman & CEO of Unicycive Therapeutics. Shalabh's experience is vast, spanning over two decades in leadership roles across the biotech landscape. He has previously served as CEO of Globavir Biosciences and CEO, Founder, Chairman and of BioCycive.Now, at the helm of Unicycive Therapeutics, Unicycive who are focused on developing new treatment options for patients with renal diseases, as kidney disease remains a major global health concer.
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry.
I’m joined by Iain Kilty, CEO of Sitryx, a biotech pushing boundaries in immunology and inflammation.
Iain’s journey is fascinating—after 22 years at Pfizer, leading global drug discovery efforts, he transitioned into biotech, taking on the CSO role at Sitryx before stepping up as CEO. Now, he’s leading the charge as Sitryx enters the clinic, a huge milestone for any company.
In this episode, we dive into:
Enjoy and stay Tuned.
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry.
I’m joined by John Mumm, CEO of Deka Biosciences—a company breaking new ground in cytokine therapies for cancer and inflammatory diseases.
John is a true veteran of biotech, with over 30 years of experience in immunotherapy research. He’s spent his career working to unlock the potential of IL-10 and cytokines, tackling one of drug development’s biggest challenges. After leadership roles at MedImmune, and ARMO BioSciences, he founded Deka to bring a fresh approach to cytokine-based treatments.
Today, we dive into John’s journey as a three-time biotech founder, the fast-moving progress at Deka, and why cytokines have been so tough to crack—until now. Plus, we get into mindset, motivation, and what it takes to build a company that lasts.
Enjoy and Stay Tuned.
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry.Melissa Sherman, CEO of MOBILion Systems—a true trailblazer shaking up separation science.Melissa was employee number one and has since raised $120M, built a world-class team, and launched Mobi, a technology that’s transforming how we analyze molecules. Think of it like upgrading from an old film camera to the latest high-definition digital—faster, clearer, and game-changing for drug developers.We dive into her inspiring journey of building MOBILion from the ground up, creating a winning company culture, and why she believes this tech is the future of separation science.Enjoy and Stay Tuned.
Our little spin off of our time at JPM!
Big announcements and exclusives! Here we have Stella Vnook, CEO of Likarda.
Listen to hear how they've been doing.
Our little spin off of our time at JPM!
Big announcements and exclusives! Here we have Patrick Alexandre, CEO of Crossject.
Listen to hear how they've been doing.
Thank you for tuning into another episode of Bio Hub! Today, we have the privilege of hosting David Esposito, a seasoned leader in the biotech industry and the CEO of ONL Therapeutics. David's experience is vast, spanning over two decades in leadership roles across the biotech landscape. He has previously served as President and CEO of Armune Biosciences, VP Commercial Operations at Thermo Fisher, and Executive Director Commercial Strategy at Merck.
Our little spin off of our time at JPM!
Big announcements and exclusives! Here we have Glen Gowers, CEO and co-Founder of Basecamp Research.
Listen to hear how they've been doing.
Our little spin off of our time at JPM!
Big announcements and exclusives! Here we have Simrit Parmar, Founder of Cellenkos.
Listen to hear how they've been doing.
